IXICO reports strong H1 revenue growth as Alzheimer’s trial demand accelerates

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden joined Stephen Gunnion to discuss the company’s interim results, growing Alzheimer’s trial demand and expanding TechBio strategy. Goorden said IXICO delivered 23% revenue growth and a 38% increase in its order book, with strong visibility into FY2026 revenues. Growth has been driven by new contracts, study extensions and increasing momentum in later-stage Alzheimer’s programmes. He also highlighted expanding opportunities in neurodegenerative diseases, including Parkinson’s, and growing partnerships in diagnostics and blood-based biomarkers for Alzheimer’s research. The interview covered IXICO’s recent £10 million fundraising and plans to scale its IXI technology platform, including the launch of version 10 with enhanced automation, processing speed and data capacity. For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications for future content. #IXICO #BramGoorden #HealthcareTechnology #TechBio #AlzheimersResearch #Parkinsons #Biotech #ClinicalTrials #AIHealthcare #MedicalImaging #LifeSciences #Investing #Pharma #Diagnostics #CRO